SANA News and Press, Sana Biotechnology Inc. From 01/16/24

2024-01-16 14:10:03 ET Summary Demand for weight loss drugs and related stocks is high, with companies like Novo Nordisk and Eli Lilly experiencing significant returns. Omega Therapeutics may be a speculative investment opportunity in the weight loss drug market as it recently ent...

2024-01-11 15:25:32 ET Summary Sana Biotechnology, Inc. raised $600m in one of the largest-ever biotech IPOs. The company's share price had deteriorated from $25, to <$3, as its in vivo and ex-vivo allogeneic therapies made slow progress or were discarded. Sana now has two ...

2024-01-11 10:49:59 ET Sana Biotechnology ( NASDAQ: SANA ) dropped ~10% in the morning hours Thursday as the cell therapy developer pared gains from a 52-week high it reached yesterday following its presentation at the J.P. Morgan Healthcare Conference. About ~3.6M SANA ...

2024-01-11 07:30:00 ET Summary Sana Biotechnology's novel T1D treatment, not requiring immunosuppression, shows encouraging results in a non-human primate study. Sana displays improved Q3 financials with a current ratio of 4.03, but faces high cash burn and potential funding needs...

2024-01-10 11:31:27 ET More on Sana Biotechnology Sana Biotechnology: SC291 Moving Forward Beyond Hematological Malignancies Sana Biotechnology: Still Early Days, Lots Of Dilution Ahead Sana gets FDA clearance to initiate clinical study for SC262 Biggest stoc...

2024-01-10 10:00:10 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and utilities could perform better in 2024 - analyst For further details see: See...

2024-01-05 15:13:56 ET Summary Additional results from a Sana Biotechnology, Inc. phase 1 study, using SC291 for the treatment of patients with B-cell lymphomas and leukemias, are expected in 2024. Initial results from phase 1 study, using SC291 for the treatment of patients with ...

2024-01-05 09:40:02 ET More on Sana Biotechnology Sana Biotechnology: Still Early Days, Lots Of Dilution Ahead Biggest stock movers today: Palantir, Peloton, Medical Properties Trust, and more Sana publishes Phase 1 data for CLL therapy in medical journal See...

SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) applica...

SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 42 nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. P...